Search

With the arrival of fixed dose formulation in 2013 and biosimilars in the near future, we wanted to realize an inventory of the use of Trastuzumab IV in real life and evaluate the overall survival (OS) of patients with metastatic breast carcinoma HER2 positive. We analyzed retrospectively epidemiological, pathological, and drug datas of patients in a French Cancer Centre (CLCC). In addition, we determined the median OS and compared the OS of extreme weight/BMI patients. The patient model was a 55-56 years old woman measuring 1.61 m, weighing 65.4 kg. Trastuzumab is mostly used as soon as the tumor status HER2+ is demonstrated, associated with a cytotoxic, docetaxel, or navelbine. Median overall survival is estimated at 44 months. Our population was superimposable to those described in pivotal studies leading to the market authorization of Trastuzumab. Patients overall survival in low/high weights and low/high BMI subgroups showed significant differences with 5% alpha risk. [ABSTRACT FROM AUTHOR]